Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

AB Science: 100% response rate in phase 1 combination therapy against AML

AB Science reports that its drug AB8939, combined with venetoclax, produced a 100% partial response rate in four hard-to-treat AML patients (1 complete remission, 1 near-complete remission, 2 partial responses). The treatment was well tolerated with no hematologic or dose‑limiting toxicity. The company plans to complete the phase 1, start an expansion study with about 15 patients, and is in discussions with regulators; AB8939 has orphan drug status in the EU and USA. InvestingPro notes a market capitalization of USD 3.57 billion and classifies AB Science as undervalued in its proprietary fair‑value model. » Mere på de.investing.com
AB Science reports promising phase‑1 data in AML with AB8939

AB Science reports that the combination of AB8939 plus Venetoclax produced a 100% partial response rate in a phase‑1 study of three patients with refractory or relapsed acute myeloid leukemia, including a complete remission after the first 14‑day cycle. The combination appeared to be well tolerated with limited hematologic toxicity. The company plans an expansion study of around 15 patients, is evaluating designs for registrational trials, and estimates an addressable market of more than €2 billion per year. » Mere på de.investing.com
AB Science: positive early data for AB8939 plus Venetoclax in refractory AML

AB Science reports that in an ongoing phase‑1 study the first three patients with refractory/relapsed acute myeloid leukemia treated with AB8939 in combination with Venetoclax achieved a 100% partial response rate after 14 days; one patient reached complete remission. Two of the patients had previously progressed on Venetoclax‑based combinations. The combination was well tolerated with no reported hematologic toxicity; the program will now proceed with dose escalation followed by an expansion phase of about 15 patients. AB8939 has orphan drug status in the EU and US; the company plans a virtual expert meeting and expects further data on October 23, after analysts have already raised their estimates. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har AB Science allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde AB Science en omsætning på 498 t € og et nettoresultat på -9,03 mio. €

(EUR)	juni 2026	YoY
Omsætning	498 t	-
Bruttofortjeneste	-208 t	-
Nettoresultat	-9,03 mio.	-
EBITDA	-10,32 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	40,14 mio. €
Antal aktier	73,25 mio.
Højeste/laveste i 52 uger	1,61 € - 0,50 €
Udbytte	Nej
Beta	1,23
P/E (PE Ratio)	-6,81
PEG (PEG Ratio)	0,06
K/I (PB Ratio)	-1,66
P/S (PS Ratio)	34,69

Virksomhedsprofil

AB Science S.A., et farmaceutisk selskab, beskæftiger sig med forskning, udvikling og markedsføring af proteinkinasehæmmere til anvendelse i human- og veterinærmedicin. Selskabets vigtigste forbindelse er masitinib, en tyrosinkinasehæmmer, der er i fase III-kliniske forsøg til behandling af prostata- og bugspytkirtelkræft, amyotrofisk lateral sklerose, multipel sklerose, Alzheimers sygdom, svær astma og mastocytose, samt i et fase II-klinisk forsøg til behandling af Covid-19. Selskabet udvikler også AB8939, en syntetisk mikrotubulusdestabilisator til behandling af akut myeloid leukæmi; og AB20001, som er i et fase 2-klinisk forsøg for at evaluere sikkerheden og virkningen af masitinib kombineret med isoquercetin hos hospitalsindlagte patienter med moderat til svær COVID-19. Selskabet markedsfører sit masitinib under varemærket Masivet i Europa. AB Science S.A. blev stiftet i 2001 og har hovedkontor i Paris, Frankrig.